drugset / Trial / NCT02321293
A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC
NaSingle-groupOpen-label
Summary
The purpose of this study is is to assess the safety and tolerability of curcumin in combination with EGFR-TKIs in selected patients with advanced non-resectable mutant EGFR NSCLC.
Timeline
- Start
- 2015-08
- Primary completion
- 2016-08
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Curcumin | Small molecule | 80 mg | Oral |
| Background | Erlotinib | Small molecule | 150 mg | Oral |
| Background | Gefitinib | Small molecule | 250 mg | Oral |